AdvanDx, Inc. Adds Enterococcal Bacteremia Assay to U.S. and E.U. Commercial Launch of QuickFISH (20 Min. Pathogen ID) Platform
1/10/2013 9:12:10 AM
WOBURN, Mass.--(BUSINESS WIRE)--AdvanDx, Inc. today announced the commercial launch of Enterococcus QuickFISH BC, a new rapid molecular diagnostic test that identifies potentially life threatening bloodstream infections caused by Enterococcus. This new QuickFISH assay is immediately available and complements the September 2012 launch of Staphylococcus QuickFISH BC for the identification of Staphylococcus aureus and coagulase-negative staphylococci. With these new products, QuickFISH can now be used to identify the causative pathogens of approximately 70% (Ann Clin Microbiol Antimicrob. 2004 May 10;3:7) of hospital acquired infections from blood cultures.